HealthEquity's Net Income Soars 806% on Strong Custodial Revenue, Cost Cuts

Ticker: HQY · Form: 10-Q · Filed: Dec 3, 2025 · CIK: 1428336

Healthequity, INC. 10-Q Filing Summary
FieldDetail
CompanyHealthequity, INC. (HQY)
Form Type10-Q
Filed DateDec 3, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentbullish

Sentiment: bullish

Topics: HSA Administration, Consumer-Directed Benefits, Financial Performance, Revenue Growth, Cost Management, Debt Reduction, Profitability

Related Tickers: HQY

TL;DR

**HealthEquity is crushing it, with net income up over 800% thanks to smart cost cuts and booming custodial revenue – buy the dip!**

AI Summary

HealthEquity, Inc. reported a significant increase in net income for the three and nine months ended October 31, 2025. For the three-month period, net income surged to $51.69 million, up from $5.70 million in the prior year, representing an 806% increase. Nine-month net income also saw substantial growth, reaching $165.46 million compared to $70.34 million in 2024, a 135% increase. Total revenue for the quarter increased by 7.2% to $322.16 million, driven by a 12.8% rise in custodial revenue to $159.07 million. Operating expenses decreased by 15.8% to $149.37 million for the quarter, primarily due to a substantial reduction in merger integration costs from $34.44 million in 2024 to $1.16 million in 2025. The company's cash and cash equivalents increased to $309.26 million as of October 31, 2025, from $295.95 million at January 31, 2025. Long-term debt decreased by $74.20 million to $982.11 million. The strategic outlook appears positive, with strong revenue growth in custodial services and effective cost management contributing to improved profitability.

Why It Matters

This robust financial performance, particularly the dramatic increase in net income and custodial revenue, signals strong operational efficiency and market penetration for HealthEquity. For investors, the significant profit growth and reduction in long-term debt make HQY a more attractive investment, demonstrating effective capital management and a clear path to profitability. Employees benefit from a more stable and growing company, potentially leading to increased opportunities. Customers gain from a leading HSA administrator that is financially sound, ensuring reliable service. In the broader market, HealthEquity's success in the consumer-directed benefits space highlights the growing demand for tax-advantaged healthcare savings, potentially intensifying competition in the sector.

Risk Assessment

Risk Level: low — The risk level is low due to significant improvements in profitability, with net income increasing by 806% for the quarter and 135% for the nine months ended October 31, 2025. The company also reduced its long-term debt by $74.20 million, strengthening its balance sheet. Furthermore, merger integration costs, a previous drag on earnings, decreased substantially from $34.44 million to $1.16 million, indicating successful integration and reduced future operational headwinds.

Analyst Insight

Investors should consider increasing their position in HealthEquity (HQY). The substantial net income growth, coupled with reduced operating expenses and debt, indicates strong financial health and operational efficiency. This filing suggests a positive trajectory for the company, making it a compelling long-term hold.

Financial Highlights

debt To Equity
0.46
revenue
$322.16M
operating Margin
26.1%
total Assets
$3,398.06M
total Debt
$982.11M
net Income
$51.69M
eps
$0.59
gross Margin
70.8%
cash Position
$309.26M
revenue Growth
+7.2%

Revenue Breakdown

SegmentRevenueGrowth
Service revenue$120.29M+0.9%
Custodial revenue$159.07M+12.8%
Interchange revenue$42.81M+6.3%

Key Numbers

Key Players & Entities

FAQ

What were HealthEquity's key revenue drivers for the quarter ended October 31, 2025?

HealthEquity's total revenue for the three months ended October 31, 2025, was $322.16 million, an increase from $300.43 million in the prior year. The primary driver was custodial revenue, which rose 12.8% to $159.07 million, alongside service revenue of $120.29 million and interchange revenue of $42.81 million.

How did HealthEquity manage its operating expenses in the recent quarter?

HealthEquity significantly reduced its total operating expenses by 15.8% to $149.37 million for the three months ended October 31, 2025, down from $177.40 million in the same period last year. This reduction was largely due to a substantial decrease in merger integration costs, which fell from $34.44 million in 2024 to $1.16 million in 2025.

What was HealthEquity's net income performance for the nine months ended October 31, 2025?

For the nine months ended October 31, 2025, HealthEquity reported net income of $165.46 million, a significant increase of 135% compared to $70.34 million for the same period in 2024. This demonstrates strong year-over-year profitability growth.

Did HealthEquity's debt position change during the period?

Yes, HealthEquity's long-term debt, net of issuance costs, decreased to $982.11 million as of October 31, 2025, from $1,056.30 million as of January 31, 2025. This represents a reduction of $74.20 million, indicating effective debt management.

What is the impact of merger integration costs on HealthEquity's recent financial results?

Merger integration costs had a significantly reduced impact on HealthEquity's recent financial results. For the three months ended October 31, 2025, these costs were $1.16 million, a substantial decrease from $34.44 million in the prior year, contributing positively to the company's improved net income.

How has HealthEquity's cash position evolved?

HealthEquity's cash and cash equivalents increased to $309.26 million as of October 31, 2025, from $295.95 million as of January 31, 2025. This growth reflects positive cash flows from operating activities, which provided $339.18 million during the nine-month period.

What are the diluted earnings per share for HealthEquity for the recent quarter?

HealthEquity's diluted net income per share for the three months ended October 31, 2025, was $0.59, a significant increase from $0.06 in the same period of 2024. This reflects the substantial growth in the company's net income.

What accounting pronouncements are HealthEquity evaluating for future impact?

HealthEquity is evaluating ASU 2023-09, 'Improvements to Income Tax Disclosures,' effective for annual periods after December 15, 2024, and ASU 2024-03, 'Disaggregation of Income Statement Expenses,' effective for annual periods after December 15, 2026. They are also evaluating ASU 2025-06, 'Targeted Improvements to the Accounting for Internal-Use Software,' effective for annual periods after December 15, 2027.

What is HealthEquity's primary business and how is it managed?

HealthEquity's primary business is administering health savings accounts (HSAs) and complementary consumer-directed benefits (CDBs). The company is managed as a single operating segment, with the Chief Executive Officer reviewing consolidated financial performance and making resource allocation decisions based on net income.

How much did HealthEquity spend on repurchases of common stock?

For the nine months ended October 31, 2025, HealthEquity repurchased $218.23 million of common stock. This is a significant increase compared to $58.51 million in repurchases during the same period in 2024, indicating a more aggressive share buyback program.

Risk Factors

Industry Context

HealthEquity operates in the rapidly growing consumer-directed healthcare market, administering HSAs and other benefits. The industry is characterized by increasing consumer engagement in healthcare spending decisions and a demand for integrated technology solutions. Key trends include consolidation among administrators and a focus on providing comprehensive platforms that simplify benefits management for employers and employees.

Regulatory Implications

The company's operations are subject to stringent regulations governing financial services and healthcare. Changes in tax laws, data privacy regulations (like HIPAA), and consumer protection laws could impact compliance requirements and operational costs. Proactive engagement with regulatory bodies and robust compliance frameworks are essential to mitigate these risks.

What Investors Should Do

  1. Monitor merger integration progress and future acquisition strategy.
  2. Analyze the drivers of custodial revenue growth.
  3. Evaluate the impact of interest rate changes on profitability.
  4. Assess the company's cost management effectiveness beyond merger integration.

Key Dates

Glossary

Health Savings Accounts (HSAs)
Tax-advantaged savings accounts that individuals can use to pay for qualified medical expenses. (Core product administered by HealthEquity, driving significant revenue.)
Consumer-Directed Benefits (CDBs)
A category of benefits, including HSAs, HRAs, and FSAs, that give consumers more control over their healthcare spending. (Broader service offering of HealthEquity beyond HSAs.)
Custodial Revenue
Revenue generated from the management and investment of funds held in HSAs and other accounts. (A key revenue stream for HealthEquity, sensitive to interest rates and asset growth.)
Merger Integration Costs
Expenses incurred when combining the operations of two companies after a merger or acquisition. (A significant factor in operating expense reduction, indicating successful integration or completion of prior integration activities.)
Diluted Earnings Per Share (EPS)
A company's net profit divided by the number of common shares outstanding, adjusted for all dilutive potential common shares. (Key profitability metric for investors, showing a substantial increase from $0.06 to $0.59 year-over-year.)
Accumulated Earnings
The total net income of a company that has not been distributed to shareholders as dividends. (Represents retained earnings, contributing to the company's equity. Decreased slightly from $209.27M to $207.94M.)
Intangible Assets
Non-physical assets that have value, such as patents, copyrights, and goodwill, often arising from acquisitions. (A significant asset category for HealthEquity, with a net value of $1,124.77 million as of October 31, 2025.)

Year-Over-Year Comparison

Compared to the prior year's filing (likely for the period ending January 31, 2025, or the comparable prior period), HealthEquity demonstrates a strong rebound in profitability, with net income for the nine months ended October 31, 2025, increasing by 135% to $165.46 million. Total revenue has also grown by 9.1% year-to-date to $978.84 million. A key factor in this improved performance is the dramatic reduction in merger integration costs, which fell from $34.44 million in the prior year's comparable quarter to just $1.16 million. This, combined with growth in custodial revenue, has led to a healthier operating margin and a significant increase in diluted EPS from $0.06 to $0.59 for the quarter.

Filing Stats: 4,400 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2025-12-03 16:04:09

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

Financial statements

Item 1. Financial statements Condensed consolidated balance sheets as of October 31, 2025 (unaudited) and January 31, 2025 3 Condensed consolidated statements of operations for the three and nine months ended October 31, 2025 and 2024 (unaudited) 4 Condensed consolidated statements of comprehensive income for the three and nine months ended October 31, 2025 and 2024 (unaudited) 5 Condensed consolidated statements of stockholders' equity for the three and nine months ended October 31, 2025 and 2024 (unaudited) 6 Condensed consolidated statements of cash flows for the nine months ended October 31, 2025 and 2024 (unaudited) 7 Notes to condensed consolidated financial statements (unaudited) 9

Management's discussion and analysis of financial condition and results of operations

Item 2. Management's discussion and analysis of financial condition and results of operations 19

Quantitative and qualitative disclosures about market risk

Item 3. Quantitative and qualitative disclosures about market risk 35

Controls and procedures

Item 4. Controls and procedures 36

OTHER INFORMATION

Part II. OTHER INFORMATION

Legal proceedings

Item 1. Legal proceedings 37

Risk factors

Item 1A. Risk factors 37

Other information

Item 5. Other information 37

Exhibits

Item 6. Exhibits 38

Signatures

Signatures 39 -2-

Financial information

Part I. Financial information

Financial statements

Item 1. Financial statements HealthEquity, Inc. and subsidiaries Condensed consolidated balance sheets (in thousands, except par value) October 31, 2025 January 31, 2025 (unaudited) Assets Current assets Cash and cash equivalents $ 309,259 $ 295,948 Accounts receivable, net of allowance for doubtful accounts of $ 918 and $ 2,070 as of October 31, 2025 and January 31, 2025, respectively 111,243 118,006 Prepaid expenses and other current assets 78,206 63,795 Total current assets 498,708 477,749 Property and equipment, net 3,390 3,239 Operating lease right-of-use assets 38,045 43,185 Intangible assets, net 1,124,768 1,204,658 Goodwill 1,648,145 1,648,145 Other assets 85,005 71,574 Total assets $ 3,398,061 $ 3,448,550 Liabilities and stockholders' equity Current liabilities Accounts payable $ 19,549 $ 14,361 Accrued compensation 43,735 69,330 Accrued liabilities 47,413 62,631 Operating lease liabilities 9,931 10,001 Total current liabilities 120,628 156,323 Long-term liabilities Long-term debt, net of issuance costs 982,105 1,056,301 Operating lease liabilities, non-current 36,228 42,219 Other long-term liabilities 23,501 22,962 Deferred tax liability 101,573 55,834 Total long-term liabilities 1,143,407 1,177,316 Total liabilities 1,264,035 1,333,639 Commitments and contingencies (see Note 5) Stockholders' equity Preferred stock, $ 0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2025 and January 31, 2025, respectively — — Common stock, $ 0.0001 par value, 900,000 shares authorized, 85,615 and 86,536 shares issued and outstanding as of October 31, 2025 and January 31, 2025, respectively 9 9 Additional paid-in capital 1,917,244 1,905,628 Accumulated other comprehensive income 8,837 — Accumulated earnings 207,936 209,274 Total stockholders' equity 2,134,026 2,114,911 Total liabilities and stockholders' equity $ 3,398,061 $ 3,448,550 See accompanying notes to condensed consolidated

Business

Business HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts ("HSAs") and complementary consumer-directed benefits ("CDBs"), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers. Principles of consolidation The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Segments The Company is managed as a single operating segment that provides administration services in connection with HSAs and other CDBs, which reflects the way in which its chief operating decision maker ("CODM"), the Chief Executive Officer, reviews the Company's financial performance and makes decisions about resource allocation. The CODM assesses the performance of the Company, monitors actual financial results against budgets, and makes resource allocation decisions with a focus on the Company's consolidated results as presented in the condensed consolidated statements of operations. The Company's measure of profitability is net income. Single segment-level financial information, including total assets, significant non-cash transactions, and capital expenditures, is contained in the accompanying condensed consolidated financial statements and related notes. The Company does not generate material international revenues. All long-lived assets are maintained in the United States of America. Basis of presentation The accompanying condensed consolidated financial statements as of October 31, 2025 and for the three and nine months ended October 31, 2025 and 2024 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing